TRML
Tourmaline Bio Inc

522
Mkt Cap
$1.23B
Volume
1.07M
52W High
$48.27
52W Low
$11.56
PE Ratio
-13.96
TRML Fundamentals
Price
$47.96
Prev Close
$47.97
Open
$47.96
50D MA
$39.15
Beta
0.97
Avg. Volume
2.02M
EPS (Annual)
-$2.89
P/B
4.75
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of Shareholders
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of...
PR Newswire·6d ago
News Placeholder
More News
News Placeholder
NVS Reports Positive Late-Stage Data on Kidney Disease Drug
Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.
Zacks·7d ago
News Placeholder
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.
Zacks·1mo ago
News Placeholder
Tourmaline Bio Stock Just Rocketed 58% Pre-Market – Here’s What Happened
Novartis has announced that it has agreed to acquire the biopharmaceutical firm, and the deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price.
Stocktwits·1mo ago
News Placeholder
Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know
The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·2mo ago
News Placeholder
Tourmaline Bio (TRML) Receives a Buy from Piper Sandler
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Tourmaline Bio (TRML Research Report), with a price targ...
TipRanks Financial Blog·1y ago
News Placeholder
The Lustgarten Foundation Appoints Two New Board Members
The Lustgarten Foundation Appoints Two New Board Members The Lustgarten Foundation Appoints Two New Board Members PR Newswire WOODBURY, N.Y., June 13, 2024 Richard Barakat, MD, and Aaron Kantoff join...
PR Newswire·1y ago
News Placeholder
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of...
Globe Newswire·2y ago
News Placeholder
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $55.60 Consensus Target Price from Analysts
Shares of Tourmaline Bio, Inc. (NASDAQ:TRML - Get Free Report) have earned an average recommendation of "Buy" from the six analysts that are currently covering the firm, Marketbeat reports. Six...
Ticker Report·2y ago
News Placeholder
Tourmaline Bio (NASDAQ:TRML) Price Target Increased to $72.00 by Analysts at Jefferies Financial Group
Tourmaline Bio (NASDAQ:TRML Free Report) had its target price raised by Jefferies Financial Group from $41.00 to $72.00 in a report released on Wednesday morning, Benzinga reports. Jefferies...
Zolmax·2y ago

Latest TRML News

View

Advertisement|Remove ads.

Advertisement|Remove ads.